Opus Genetics CEO George Magrath Sells Nearly 9,500 Shares in Tax Withholding Transaction

Automatic Share Sale to Cover Tax Obligations

George Magrath, who serves as both Director and Chief Executive Officer of Opus Genetics, Inc., executed a share sale on July 23, 2026, that the company characterizes as automatic and non-discretionary. The filing discloses that the 9,475 shares were sold by the company on Magrath's behalf as required to satisfy tax withholding obligations arising from a vesting and settlement event associated with a restricted stock unit award. This type of transaction is a standard practice at many public companies, allowing executives to satisfy tax liabilities without directly initiating a sale order themselves.

The disclosure emphasizes that this transaction does not represent a voluntary or discretionary trade by the reporting person. Instead, it reflects an administrative action taken by Opus Genetics to handle the tax consequences of equity compensation vesting. Under applicable securities regulations, such automatic sales are treated differently from director or officer trades that reflect personal investment decisions or market views.

Transaction Pricing and Share Volume Details

The shares were sold across multiple transactions on July 23, 2026, at prices ranging from a low of $2.9009 per share to a high of $3.025 per share. The filing reports a weighted average price of $2.9473 across all transactions. The reporting person undertakes to provide the issuer, any shareholder, or the Securities and Exchange Commission staff with detailed information regarding the specific number of shares sold at each individual price point within the stated range, should such information be requested.

The relatively narrow trading range of approximately $0.12 per share between the low and high prices suggests the sales likely occurred over a relatively short trading window, consistent with the automatic execution nature of the transaction. This pricing information provides investors with transparency regarding the valuation at which the CEO's shares were disposed of in connection with the tax withholding event.

Magrath's Beneficial Ownership Position Post-Transaction

Following the July 23, 2026 sale, George Magrath maintains direct beneficial ownership of 1,731,869 common shares of Opus Genetics. This figure represents his shareholding after the automatic sale of 9,475 shares to satisfy tax obligations. The disclosure indicates that all shares are held directly by Magrath rather than through any indirect ownership structures or entities.

The substantial remaining shareholding suggests that Magrath retains a significant financial stake in the company despite the share disposition related to tax withholding. Investors monitoring executive ownership levels may note that the CEO's ownership position remains material relative to the overall company capitalization, though the specific percentage ownership is not disclosed in this filing.

Restricted Stock Unit Vesting and Equity Compensation

The transaction detailed in this disclosure arose from the vesting and settlement of a restricted stock unit award granted to Magrath. Restricted stock units are a common form of equity compensation for executives and senior officers at public companies. When RSUs vest, they typically convert into actual shares of common stock, at which point the recipient becomes liable for income taxes on the value of the vested shares.

Rather than requiring the executive to arrange separate financing to cover the resulting tax liability, many companies authorize automatic share sales sufficient to generate the necessary withholding proceeds. This approach simplifies the administrative process and eliminates the timing risk or market execution concerns that might arise if executives were required to sell shares independently to raise tax funds. The filing's explanation confirms this was the purpose of the July 23, 2026 transaction.

Executive Leadership Role and Regulatory Filing Requirements

George Magrath's status as both a Director and Chief Executive Officer of Opus Genetics places him within the category of persons required to report changes in beneficial ownership under Section 16(a) of the Securities Exchange Act of 1934. Form 4 filings are the standard mechanism by which company insiders—including officers and directors—disclose transactions in company securities to the investing public and regulatory authorities.

The filing was signed on behalf of Magrath by Amy Rabourn, acting under power of attorney, on July 27, 2026, three business days after the transaction occurred. This timing is consistent with the standard five-calendar-day filing deadline for insider transactions under current SEC rules. The use of a power of attorney for signature indicates a delegated administrative arrangement common at larger public companies.

Transparency in Insider Trading Disclosures

The detailed disclosure of transaction prices, including the range of prices at which shares were sold and the weighted average, demonstrates the transparency requirements applied to insider transactions. By specifying that shares sold at multiple price points within a narrow range, the filing allows investors to assess the market conditions under which the CEO's shares were disposed. The company's undertaking to provide granular detail on request further enhances the audit trail available for regulatory and shareholder review.

Form 4 filings serve an important informational function for market participants monitoring executive and director trading activity. While automatic sales triggered by tax withholding are distinguished from discretionary trades in market commentary, they remain significant data points for investors assessing insider sentiment and ownership changes at public companies. The transparency of these disclosures allows the investing public to evaluate whether executive shareholdings are increasing or decreasing over time.

No Material Adverse Change Indicated

The filing contains no indication of material adverse developments at Opus Genetics or changes in the company's operational or financial condition. The transaction is presented purely as an administrative response to the tax consequences of equity compensation vesting. No forward-looking statements, guidance revisions, or adverse business disclosures accompany this insider trading report.

Investors should note that the existence of an insider share sale, even in the context of automatic tax withholding, does not inherently signal positive or negative views about the company's prospects. Automatic sales of this nature are mechanically triggered by vesting events and tax obligations rather than by executive discretion regarding share value. The filing provides no basis for inferring management sentiment about future stock performance.

Ongoing Regulatory Obligations and Record Keeping

The Form 4 filing demonstrates Opus Genetics' compliance with federal securities laws governing insider transaction reporting. The disclosure confirms that the company maintains systems to track and report changes in beneficial ownership by insiders and that these disclosures are made available to the public through regulatory filings databases such as EDGAR.

The notation that Magrath is not marked as ceasing to be subject to Section 16 reporting obligations indicates he remains in a position—either as Director, Officer, or both—that subjects him to ongoing insider trading rules and disclosure requirements. Investors seeking to monitor executive shareholding activity at Opus Genetics will continue to have access to Form 4 filings documenting any future transactions by Magrath or other company insiders.